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To the Editor 
Dr Spence alerts the readers of the journal of the possibility that the association between statin use and 
increased risk of cataract reported in our recently published paper [1] is flawed by the presence of 
indication bias. It is well known that indication bias is often a threat to the validity in observational studies 
[2] if the indication for the medication under study is associated with the outcome of interest [3], and we 
agree that randomized clinical trials are the gold standards for the patients enrolled in the trial. 
It should be argued that, although clinical trials are not affected by indication bias and the randomization 
guarantees the control of all potential confounders, they suffer from inherent limitations, as they are not 
designed specifically to detect adverse events, so their number, the duration of follow-up, or the criteria for 
adverse events recording can hinder risk detection [4]. In our opinion, it is important to critically consider 
the evidence arising from different types of study, taking into account the specific limitations. A typical 
example is the incidence of muscle side effects with statins, which seldom occur in RCTs but are much more 
prevalent in the free living population [5, 6]. 
 
Since indication bias affects mainly the results obtained by studies comparing users of a certain drug with 
non-users, in our study we controlled for this bias using a case control study nested into a cohort of new-
users of statins. Therefore, all enrolled patients have been prescribed with statin, then all likely suffering 
from hypercholesterolemia. We observed that subjects with treatment coverage (adherence) of at least 
50% of the observation period have about a 20% increased risk compared to subjects with a coverage of 
<25% (and dyslipidemic), suggesting a dose/exposition effect [1]. In our case, a possible indication bias 
could be conceivable if the increased risk was due to a greater severity of hypercholesterolemia, assuming 
that the greater severity is associated with a greater adherence. This assumption, however, lacks 
confirmation [7], also considering that asymptomatic disease deprives the patient a motivational boost. 
Moreover, a rule-out analysis [8] was carried out to assess if the adjustment for severity of 
hypercholesterolemia (unmeasured confounder) could fully explain the observed association between high 
adherence to statin treatment and cataract. We considered different prevalence of the unmeasured 
confounder in the population (from 20% to 80% by 20%), an exposure prevalence of 25% and an observed 
association measure between high adherence to statin treatment and cataract of 1.196. The results showed 
that cataract risk among patients with high cholesterol levels should be at least 2.5 fold higher than patients 
with low cholesterol levels to allow severe hypercholesterolemia to be fully responsible for the association 
observed in our analysis for all scenarios. Since this value seems to be unrealistic, it is unlikely that high 
adherence to statin treatment is not associated to cataract onset.  A literature survey does not 
unequivocally indicate the role of high levels of cholesterol as a risk factor for cataracts. Furthermore, in 
patients with very high cholesterol levels, such as in patients with familial hypercholesterolemia, however, 
there is no evidence for increase prevalence of cataract [9]. On the other hand, in some studies, the 
presence of cataract was found to be associated with high levels of cholesterol and oxidative stress [10]. 
Cholesterol representing about 40% of the total lipids of human lens fibers [11], so factors modifying its 
level and/or repartition may alter optical lens properties. In his review Cenedella [12] describes how 
inherited defects in enzymes of cholesterol metabolism and use of drugs which inhibit lens cholesterol 
biosynthesis may be associated with cataracts in animals and men.  
 
Finally, the aim of the article is not to warn against the use of statins [13] but simply alert the scientific 
community that under circumstances differing from those of RCTs statin treatment could result in an 
increased risk of developing cataracts. Whether concomitant drug treatments and other circumstances can 
explain and confirm these findings remains to be addressed.  
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